EMA Panel Gives Thumbs-up to Fenofibrate/Simvastatin ComboEMA Panel Gives Thumbs-up to Fenofibrate/Simvastatin Combo

The drug, known as Cholib, received a "positive opinion" from CHMP for two doses of the fenofibrate/simvastatin combination. A positive opinion is a prerequisite to approval by the European Commission, which has 67 days from the date of the opinion to grant approval. International Approvals
Source: Medscape Cardiology Headlines - Category: Cardiology Tags: Cardiology News Alert Source Type: news

Related Links:

Controlling lipids, in particular cholesterol and low-density lipoprotein cholesterol, has been identified as a key intervention to prevent adverse systemic events in patients with a high atherosclerotic burden and claudication. It is unclear if goal-directed therapy of to achieve a decrease in cholesterol (
Source: Journal of Vascular Surgery - Category: Surgery Authors: Tags: Abstract from the 2018 Eastern Vascular Society Annual Meeting Source Type: research
Molecular actions of PPARα in lipid metabolism and inflammation. Endocr Rev. 2018 Jul 17;: Authors: Bougarne N, Weyers B, Desmet SJ, Deckers J, Ray DW, Staels B, De Bosscher K Abstract Peroxisome proliferator-activated receptor alpha (PPARα) is a nuclear receptor of clinical interest as a drug target in various metabolic disorders. PPARα also exhibits marked anti-inflammatory capacities. The first generation PPARα agonists, the fibrates, have however been hampered by drug-drug interaction issues, statin drop-in and ill-designed cardiovascular intervention trials. Notwithstanding...
Source: Endocrine Reviews - Category: Endocrinology Tags: Endocr Rev Source Type: research
Publication date: Available online 19 July 2018Source: Canadian Journal of CardiologyAuthor(s): G. B. John Mancini, Alice Y. Cheng, Kim Connelly, David Fitchett, Ronald Goldenberg, Shaun Goodman, Lawrence A. Leiter, Eva Lonn, Breay Paty, Paul Poirier, James Stone, David Thompson, Subodh Verma, Vincent Woo, Jean-Francois YaleAbstractA sea-change in the management of diabetes is occurring with the publication of clinical trials showing unequivocal cardiovascular (CV) protection through the use of certain antihyperglycemic agents. This change is similar to the change that occurred when lipid lowering with statins was first sh...
Source: Canadian Journal of Cardiology - Category: Cardiology Source Type: research
Unfortunately the name of one of the authors was spelled incorrectly in the published original article. The correct name is Alejandro Santos-Lozano. The original article got updated.
Source: Journal of Inherited Metabolic Disease - Category: Internal Medicine Source Type: research
Publication date: Available online 18 July 2018Source: European UrologyAuthor(s): Teemu J. Murtola, Heimo Syvälä, Teemu Tolonen, Mika Helminen, Jarno Riikonen, Juha Koskimäki, Tomi Pakarainen, Antti Kaipia, Taina Isotalo, Paula Kujala, Teuvo L.J. TammelaAbstractWe tested whether intervention with atorvastatin affects the prostate beneficially compared with placebo in men with prostate cancer in a randomized clinical trial. A total of 160 statin-naïve prostate cancer patients scheduled for radical prostatectomy were randomized to use 80 mg atorvastatin or placebo daily from recruitment to surgery fo...
Source: European Urology - Category: Urology & Nephrology Source Type: research
Updated Date: Jul 19, 2018 EST
Source: DailyMed Drug Label Updates - Category: Drugs & Pharmacology Source Type: alerts
AbstractPurposeClinical guidelines specify who should receive high-intensity statins; however, it is unclear how high-intensity statins are used in Australia. Our objective was to determine the demographic, clinical, and lifestyle factors associated with high-intensity statin therapy in Australia.MethodsData from the Australian Diabetes, Obesity and Lifestyle study collected in 2011 –2012 were analyzed. High-, moderate-, and low-intensity statins were defined as use of statins at doses demonstrated to reduce low-density lipoprotein cholesterol levels by>  50, 30–50, and  2 alcoholic drinks dail...
Source: European Journal of Clinical Pharmacology - Category: Drugs & Pharmacology Source Type: research
International Journal of Geriatric Psychiatry, EarlyView.
Source: International Journal of Geriatric Psychiatry - Category: Geriatrics Authors: Source Type: research
Source: The Journal of Thoracic and Cardiovascular Surgery - Category: Cardiovascular & Thoracic Surgery Authors: Source Type: research
AbstractMedication nonadherence is a significant clinical problem among individuals taking statins. Poor adherence is often attributable to several reasons, yet most adherence interventions target a single reason. Baseline data were examined from a randomized clinical trial of 236 patients with hyperlipidemia. A latent class analysis was then performed on patients reporting any nonadherence (n  = 109). A 4-class solution provided the most optimal fit and differentiation of classes. Class 1 (N = 59, 54%) included patients who reported occasionally forgetting. Class 2 (N = 16, 14%) r...
Source: Journal of Behavioral Medicine - Category: Psychiatry Source Type: research
More News: Cardiology | Fenofibrate | Grants | Heart | Simvastatin | Statin Therapy | Tricor | Zocor